• Osteopore reports record AUD 835K revenue in Q2 CY25, up 15% QoQ and 11% YoY
• Secures EU MDR clearance for custom orthopaedic and cranial implants, unlocking new revenue streams
• Partners with Queensland Children's Hospital and Princess Alexandra Hospital for clinical studies

Osteopore Ltd (ASX:OSX) has reported a strong financial performance in Q2 CY25, posting record quarterly revenue of AUD 835K, representing 15% growth quarter-on-quarter and 11% year-on-year. The company's revenue growth was driven by strong product adoption in the APAC region, which accounted for over 90% of total revenue, with the majority contribution coming from the established business units of craniofacial surgery and aesthetic surgery. Osteopore also saw a significant boost from its partnership with Zimmer Biomet, with product sales in the first 12 months (H1 2024 to H1 2025) growing threefold above the previous 12-month period. Additionally, the company secured European Medical Device Regulation (EU MDR) clearance to supply its cutting-edge custom orthopaedic and cranial implants, expanding opportunities to offer high-value, custom implants to the European market alongside its off-the-shelf products, unlocking new revenue streams. Osteopore also announced new clinical partnerships with Queensland Children's Hospital and Princess Alexandra Hospital in Australia, which will explore the use of Osteopore's 3D-printed regenerative implants in temporal hollowing augmentation and mandible reconstruction procedures.

Osteopore has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.

The announcement does not provide any comprehensive forward-looking outlook statements. However, it does mention that the European orthopaedic market is projected to grow at a CAGR of 3.3% by 2029, while the cranial implant market is expected to grow at a CAGR of 9.4% by 2030, which could present opportunities for Osteopore's expansion in these markets.